Two Cities, Two Conferences: SanegeneBio to Present at Two Premier Healthcare Conferences This September
BOSTON, SHANGHAI, and SUZHOU – August 25, 2025, SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, announced that it will be participating in two premier industry conferences this September—Morgan Stanley 23rd Annual Global Healthcare Conference and RNA Leaders USA 2025.
The SanegeneBio executive team will represent the company in these conference sessions to share the latest advancements and future strategy of our RNAi technology, as well as participate in discussions on technological developments.
— Morgan Stanley 23rd Annual Global Healthcare Conference
Unplugged Fireside Chat
Weimin Wang, CEO and Founder; Shiyu Wang, CSO and Cofounder; Marc Abrams, CTO and Head of US Operations
Time: 7:45 AM – 8:20 AM EST | Tuesday, September 9, 2025
— RNA Leaders USA 2025
Oral Presentation——”Innovative RNAi Strategies for C3 Reduction: Clinical Insights and Delivery Advances”
Marc Abrams, CTO and Head of US Operations
Time: 2:25 PM – 2:50 PM EST | Wednesday, September 10, 2025
